Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials
Abstract
Introduction Thiazolidinedione (TZD) is one of the therapy options for polycystic ovary syndrome (PCOS) patients; however, the effectiveness of TZD in the treatment of PCOS remains controversial. The aim of this metaanalysis was to clarify the role that TZDs play in the treatment of PCOS.Methods The authors searched the following databases for any date up to June 2012 for randomized controlled trials on PCOS treatment in which interventions for the experimental and control groups were TZDs and placebo, respectively: Medline, Embase, and the Cochrane library.Results The search strategy identified 173 potential publications, eight of which were included. In the treatment of PCOS, the insulin-lowering effects of TZDs were superior to placebo (95% CI -1.50 to -0.12; P=0.021), and the lowering of fasting blood glucose was superior to placebo (95% CI -1.06 to -0.05; P=0.031). There was no difference in reduction of the Ferriman-Gallwey scores or the androgen levels between TZDs and placebo (95% CI -0.57 to 0.10; P=0.169 and 95% CI -0.64 to 0.09; P=0.141, respectively). The effects of TZDs on body weight reduction were inferior to placebo (95% CI 0.13 to 0.66; P=0.003). Significant between-study heterogeneity was detected for several variables assessed.Conclusion This is the first meta-analysis to evaluate the role that TZDs plays in the treatment of PCOS compared with placebo. The currently available data showed that TZDs can effectively reduce insulin and fasting blood glucose levels in patients with PCOS, but TZDs may not effectively reduce the Ferriman-Gallwey score or androgen levels and may increase body weight.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A meta-analysis by Du et al. of six studies with 219 patients showed that pioglitazone and rosiglitazone were more effective than placebo in reducing fasting blood glucose levels, with mean difference −0.55 mmol/l (95% CI −1.06 to −0.05; p = 0.031).
“With respect to the placebo, pioglitazone and rosiglitazone were more effective than placebo in reducing FBG levels (MD: −0.55 mmol/l; 95% CI −1.06 to −0.05; p = 0.031).”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [63]
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554 · see citing works
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · see citing works
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · see citing works
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050 · see citing works
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · see citing works
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works
Clinical assessment of body hair growth in women.
Ferriman, D., & Gallwey, J. D. (1961) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,556 · see citing works
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463 · see citing works
Random-effects model for meta-analysis of clinical trials: An update
DerSimonian, R., & Kacker, R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.04.004 · Cited by 2,374 · see citing works
Men at risk: occupation and male infertility.
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,219 · see citing works
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · see citing works
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864 · see citing works
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625 · see citing works
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 590 · see citing works
Vgontzas, A. N., Bixler, E. O., & Chrousos, G. P. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01177.x · Cited by 321 · see citing works
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · see citing works
Baillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300 · see citing works
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239 · see citing works
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
QUINN, C. E., Hamilton, P., Lockhart, C., & McVeigh, G. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707452 · Cited by 165 · see citing works
Chenevix‐Trench, G., Fearnley, E., Marquart, L., Spurdle, A. B., Weinstein, P., & Webb, P. M. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9658-7 · Cited by 161 · see citing works
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed, W., Ziouzenkova, O., Brown, J. D., Devchand, P. R., Francis, S. A., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F. J., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01825.x · Cited by 151 · see citing works
CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure
Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., & Bass, N. M. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005405526283 · Cited by 111 · see citing works
Rautio, K., Tapanainen, J. S., Ruokonen, A., & Morin-Papunen, L. C. (2006) · Human Reproduction · doi:10.1093/humrep/dei505 · Cited by 88 · see citing works
Schoppee, P. D., Garmey, J. C., & Veldhuis, J. D. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.1.190 · Cited by 86 · see citing works
Pioglitazone and bladder cancer: a propensity score matched cohort study
Wei, L., MacDonald, T. M., & Mackenzie, I. S. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04325.x · Cited by 86 · see citing works
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
Stein, L. L., Dong, M. H., & Loomba, R. S. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0072-z · Cited by 85 · see citing works
Naka, K. Κ., Kalantaridou, S., Kravariti, M., Bechlioulis, A., Kazakos, N., Calis, K. A., Makrigiannakis, A., Katsouras, C. S., Chrousos, G. P., Tsatsoulis, A. A., et al. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.06.058 · Cited by 79 · see citing works
Aroda, V. R., Ciaraldi, T. P., Burke, P., Mudaliar, S., Clopton, P., Phillips, S., Chang, R. J., & Henry, R. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1133 · Cited by 71 · see citing works
Glintborg, D., Hermann, A. P., Andersen, M., Hagen, C., Beck‐Nielsen, H., Veldhuis, J. D., & Henriksen, J. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.12.067 · Cited by 68 · see citing works
Li, X.-J., Yu, Y.-X., Liu, C.-Q., Zhang, W., Zhang, H.-J., Yan, B., Wang, L.-Y., Yang, S.-Y., & Zhang, S.-H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03917.x · Cited by 67 · see citing works
Self-citationChang, A. Y., Ayers, C. R., Minhajuddin, A., Jain, T., Nurenberg, P., de Lemos, J. A., Wild, R. A., & Auchus, R. J. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03907.x · Cited by 64 · see citing works
Risk of Fractures with Glitazones
Bodmer, M., Meier, C., KRAENZLIN, M. E., & Meier, C. R. (2009) · Drug Safety · doi:10.2165/00002018-200932070-00001 · Cited by 61 · see citing works
Gangalè, M. F., Miele, L., Lanzone, A., Sagnella, F., Martínez, D., Tropea, A., Moro, F., Morciano, A., Ciardulli, A., Palla, C., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04093.x · Cited by 53 · see citing works
Troglitazone (Rezulin) and hepatic injury
Faich, G. A., & Moseley, R. H. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.652 · Cited by 51 · see citing works
Phelan, N., O’Connor, A. S., Tun, T. K., Correia, N., Boran, G. P., Roche, H. M., & Gibney, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2444 · Cited by 46 · see citing works
Aigner, E. S., Bachofner, N., Klein, K., Geyter, C. D., Hohla, F., Patsch, W., & Datz, C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2156 · Cited by 44 · see citing works
Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients
Koenen, T. B., Tack, C. J., Kroese, J. M., Hermus, A. R., Sweep, F. C. G. J., van der Laak, J. A. W. M., Stalenhoef, A. F. H., Graaf, J. D., van Tits, L. J. H., & Stienstra, R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0517 · Cited by 40 · see citing works
Atiomo, W., Read, A., Golding, M., Silcocks, P., Razali, N., Sarkar, S., Hardiman, P., & Thornton, J. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.05.001 · Cited by 28 · see citing works
Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome
Kim, J., Choi, Y. M., Cho, Y. M., Jung, H. S., Chae, S. J., Hwang, K. R., Hwang, S.-S., Ku, S., Kim, S. H., Kim, J. G., et al. (2012) · Human Reproduction · doi:10.1093/humrep/des039 · Cited by 25 · see citing works
Late-onset troglitazone-induced hepatic dysfunction.
Bell, D. S. H., & Ovalle, F. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.128 · Cited by 21 · see citing works
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
Liao, L., Tian, Y., Zhao, J., Xin, Y., Xing, H.-Y., & Dong, J. (2011) · PubMed · Cited by 19 · see citing works
Ko, G. T. C., Tsang, P. C. C., Wai, H. P. S., Kan, E. C. Y., & Chan, H. C.-K. (2006) · Advances in Therapy · doi:10.1007/bf02850321 · Cited by 18 · see citing works
Rajkhowa, M., & Clayton, R. N. (1995) · Current Obstetrics and Gynaecology · doi:10.1016/s0957-5847(95)80003-4 · Cited by 17 · see citing works
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc10-2235 · Cited by 11 · see citing works
[Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome].
Ma, L., Jin, L., Yu, Q., & Xu, L. (2007) · PubMed · Cited by 8 · see citing works
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5 · see citing works
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome
Liao, Lin, Tian, Yongjie, Zhao, Jiajun, Xin, Ying, Y., Xing, Haiyang, et al. (2011) · 中华医学杂志：英文版 · Cited by 1 · see citing works
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083 · see citing works
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · see citing works
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676 · see citing works
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557 · see citing works
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442 · see citing works
The pathogenesis and treatment of polycystic ovary syndrome: What’s new?
Bednarska, S., & Siejka, A. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/59380 · Cited by 284 · see citing works
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 272 · see citing works
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123 · see citing works
Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility
Vitti, M., Emidio, G. D., Carlo, M. D., Carta, G., Antonosante, A., Artini, P. G., Cimini, A., Tatone, C., & Benedetti, E. (2016) · PPAR Research · doi:10.1155/2016/4612306 · Cited by 84 · see citing works
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65 · see citing works
Current and experimental drug therapy for the treatment of polycystic ovarian syndrome
Corte, L. D., Foreste, V., Barra, F., Gustavino, C., Alessandri, F., Centurioni, M. G., Ferrero, S., Bifulco, G., & Giampaolino, P. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1781815 · Cited by 58 · see citing works
Polycystic Ovary Syndrome (PCOS): Symptoms, Causes, and Treatment
Bai, H., Ding, H., & Wang, M. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5105126 · Cited by 57 · see citing works
Xu, Q., Zhang, J., Lu, Y., & Wu, L. Y. (2024) · iScience · doi:10.1016/j.isci.2024.108783 · Cited by 41 · see citing works
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38 · see citing works
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35 · see citing works
Zuuren, E. J., & Fedorowicz, Z. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14486 · Cited by 35 · see citing works
Artini, P. G., Obino, M. E. R., Sergiampietri, C., Pinelli, S., Papini, F., Casarosa, E., & Cela, V. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1431122 · Cited by 33 · see citing works
Przybycień, P., Gąsior‐Perczak, D., & Placha, W. (2022) · Cells · doi:10.3390/cells11162569 · Cited by 26 · see citing works
Bogacka, I., Bogacki, M., Gaglewska, M., Kurzyńska, A., & Wasielak, M. (2013) · PubMed · Cited by 24 · see citing works
Tay, C. T., Joham, A. E., Hiam, D., Gadalla, M. A., Pundir, J., Thangaratinam, S., Teede, H. J., & Moran, L. (2018) · Clinical Endocrinology · doi:10.1111/cen.13753 · Cited by 23 · see citing works
Shi, M., Li, X., Xing, L., Li, Z., Zhou, S., Wang, Z., Zou, X., She, Y., Zhao, R., & Qin, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121556 · Cited by 20 · see citing works
Floyd, R., Gryson, R., Mockler, D., Gibney, J., Duggan, S. N., & Behan, L. (2022) · International Journal of Endocrinology · doi:10.1155/2022/2830545 · Cited by 16 · see citing works
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Romualdi, D., Versace, V., & Lanzone, A. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120908709 · Cited by 17 · see citing works
Polycystic ovary syndrome and metabolic syndrome: the worrisome twosome?
Shah, D., & Rasool, S. (2015) · Climacteric · doi:10.3109/13697137.2015.1116505 · Cited by 13 · see citing works
Hara, S., Takahashi, T., Amita, M., Matsuo, K., Igarashi, H., & Kurachi, H. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-69 · Cited by 13 · see citing works
Polycystic Ovary Syndrome: A Brief Review with Recent Updates
Shermin, S., Noor, A., & Jahan, S. (2020) · Delta Medical College Journal · doi:10.3329/dmcj.v7i2.45567 · Cited by 14 · see citing works
Bashir, R., Wani, I. A., & Ganie, M. A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220518150754 · Cited by 11 · see citing works
森下, 美., Endo, T., Baba, T., Kuno, Y., Ikeda, K., Kiya, T., Honnma, H., & Saito, T. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0395-y · Cited by 11 · see citing works
Kumbhar, P., Chavan, R., Darekar, S., Kolekar, K. A., Sequeira, A., Vishwas, S., Gupta, G., Paudel, K. R., Singh, S. K., Dua, K., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03578-7 · Cited by 9 · see citing works
Kurzyńska, A., Bogacki, M., Chojnowska, K., & Bogacka, I. (2016) · Czech Journal of Animal Science · doi:10.17221/95/2015-cjas · Cited by 9 · see citing works
Ganie, M. A., Rashid, A., Sood, M., Sofi, N. Y., Wani, I. A., Nisar, S., Butt, T. P., Gupta, N., Bhat, D., Choh, N. A., et al. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1675044 · Cited by 7 · see citing works
Permadi, W., Hestiantoro, A., Ritonga, M. A., Ferrina, A., Iswari, W. A., Sumapraja, K., Muharram, R., Djuwantono, T., Wiweko, B., & Tjandrawinata, R. R. (2021) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_141_20 · Cited by 7 · see citing works
Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156245 · Cited by 7 · see citing works
Recent advances in therapeutic interventions of polycystic ovarian syndrome
Lad, S. U., Vyas, G., Mohd, S., Mishra, V. K., Wadhwa, S., Singh, S., & Harish, V. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100543 · Cited by 6 · see citing works
Diabetes advice for women with polycystic ovary syndrome: prevention, prevention, prevention
Mani, H., Khunti, K. K., Levy, M. J., & Davies, M. J. (2013) · Diabetes Management · doi:10.2217/dmt.13.54 · Cited by 5 · see citing works
Polycystic Ovary Syndrome (PCOS)
Hechtman, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00209-0 · Cited by 6 · see citing works
Role of leptin and nuclear receptor PPARγ in PCOS pathogenesis
Ievleva, K., Николаевна, Д. И., & Сутурина, Л. В. (2020) · Problems of Endocrinology · doi:10.14341/probl12620 · Cited by 4 · see citing works
Jin, Y., Hu, H., Zhang, J.-C., Xin, X., Zhu, Y., Zhang, H., Fan, R., Yang, Y., & Li, D. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2405098 · Cited by 3 · see citing works
The polycystic ovary syndrome: a position statement from the European Society of
Conway, G. S., Dewailly, D., Diamanti‐Kandarakis, E., Franks, S., Gambineri, A., Keleştimur, F., Μacut, D., Micić, D., Pasquali, R., Pfeifer, M., et al. (2014) · Cited by 3 · see citing works
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3 · see citing works
The metabolic effects of drugs used for the treatment of polycystic ovary syndrome
Karaköse, M., Çakal, E., Ertan, K., & Delibaşı, T. (2013) · Journal of the Turkish-German Gynecological Association · doi:10.5152/jtgga.2013.57701 · Cited by 3 · see citing works
Polycystic ovary syndrome and obesity: a modern paradigm
Khamoshina, M. B., Artemenko, Y. S., Bayramova, A. A., Андреевна, Р. В., & Orazov, M. R. (2022) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2022-26-4-382-395 · Cited by 3 · see citing works
Zohora, F. T., Mou, S. S., Haque, M. R., Baidya, M., Jahan, I., & Al-Mamun, M. E. (2025) · Translational Medicine of Aging · doi:10.1016/j.tma.2025.08.005 · Cited by 2 · see citing works
Romualdi, D., Versace, V., Lanzone, A., & Longhi, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-31307-3_16 · Cited by 2 · see citing works
Синдром поликистозных яичников. Официальное заявление Европейского общества эндокринологии
Conway, G. S., Dewailly, D., & Diamanti‐Kandarakis, E. (2015) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy · doi:10.18370/2309-4117.2015.25.32-52 · Cited by 1 · see citing works
Actualización del Síndrome de Ovario Poliquístico y su importancia en Dermatología
María Teresa Molina, C., Daniela Carvajal, A., & Javier Fernández, M. (2015) · Revista Chilena de Dermatología · doi:10.31879/rcderm.v31i4.21
Roy, M., Mazumder, R., Singh, N., Bhardwaj, S., Mishra, R., Mishra, R., & Kumar, B. (2024) · Current Drug Therapy · doi:10.2174/0115748855313334240827071434
- Authors
- Du, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Du, Qiang
- Venue
- Advances in Therapy
- Published
- 2012-08-28
- Volume
- 29
- Issue
- 9
- Pages
- 763-774
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2030289403
- Cited by
- 47
- References
- 50
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 2 · 2022: 6 · 2021: 1 · 2020: 7 · 2019: 2 · 2018: 5 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 2 · 2013: 4
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Advances in Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
- Keywords
- thiazolidinediones, polycystic ovary syndrome, fasting blood glucose, androgen levels, Ferriman-Gallwey score, weight loss, insulin resistance, PCOS treatment
- MeSH terms
- Rosiglitazone, Pioglitazone, Androgens, Blood Glucose, Body Weight, Female, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Randomized Controlled Trials as Topic, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
